Recruiting
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707· Phase 3· GlaxoSmithKline· Source
Contact: Rashid Atique (principal investigator)
Recruiting
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
NCT07791043· Phase 2· GlaxoSmithKline· Source
Contact: Eric Lawitz (principal investigator)
Recruiting
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993· Phase 3· GlaxoSmithKline· Source
Contact: Robert Morin Jr (principal investigator)
Recruiting
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892· Phase 3· GlaxoSmithKline· Source
Contact: Robert Morin Jr (principal investigator)
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395· Phase 2· GlaxoSmithKline· Source
Contact: Jeff Bullock (principal investigator)
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· Phase 3· GlaxoSmithKline· Source
Contact: Robert Jacobs (principal investigator)
Recruiting
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
NCT07358546· Phase 1· GlaxoSmithKline· Source
Contact: Eric Lawitz (principal investigator)
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188· Phase 3· GlaxoSmithKline· Source
Contact: Robert Morin Jr (principal investigator)
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227· Phase 3· GlaxoSmithKline· Source
Contact: Robert Morin Jr (principal investigator)
Active, not recruiting
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
NCT07168356· Phase 1· GlaxoSmithKline· Source
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· Phase 3· GlaxoSmithKline· Source
Contact: Craig Boyle (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Drew Rasco (principal investigator)
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043· Phase 2· GlaxoSmithKline· Source
Contact: Eric Lawitz (principal investigator)
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· Phase 3· GlaxoSmithKline· Source
Contact: John Renshaw (principal investigator)
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Eric Lawitz (principal investigator)
Recruiting
First Time in Human Study of Long Acting VH4524184 Formulations
NCT06310551· Phase 1· ViiV Healthcare· Source
Contact: Robert Bass (principal investigator)
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Krishna Alluri (principal investigator)
Active, not recruiting
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
NCT05371080· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051· Phase 1· GlaxoSmithKline· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source